



**Supplementary Figure 4.** Forest plots of the (A) overall mortality rate, (B) hepatocellular carcinoma, (C) cardiovascular outcome, (D) liver decompensation, (E) cirrhosis, (F) extrahepatic cancer, and (G) any cancer risk incidence in lean individuals with MASLD compared to overweight individuals with MASLD. MASLD, metabolic dysfunction-associated steatotic liver disease.

